Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Johnson-and-Johnson stock in Canada | $165.97

Own Johnson-and-Johnson shares in just a few minutes.

Johnson & Johnson
NYSE: JNJ - USD
DRUG MANUFACTURERS-GENERAL
$172.25
+$0.07 (+0.04%)

Johnson-and-Johnson is a drug manufacturers-general business based in the US. Johnson-and-Johnson stocks (JNJ.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $172.18 – a decrease of 1.94% over the previous week. Johnson-and-Johnson employs 136,000 staff and has a trailing 12-month revenue of around $89.2 billion.

How to buy Johnson-and-Johnson stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: JNJ in this case.
  5. Research Johnson-and-Johnson stocks. The platform should provide the latest information available.
  6. Buy your Johnson-and-Johnson stocks. It's that simple.

How has Coronavirus impacted Johnson-and-Johnson's stock price?

Since the stock market crash in March caused by coronavirus, Johnson-and-Johnson's stock price has had significant positive movement.

Its last market close was $165.97, which is 9.66% up on its pre-crash value of $149.93 and 52.04% up on the lowest point reached during the March crash when the stocks fell as low as $109.16.

If you had bought $1,000 worth of Johnson-and-Johnson stocks at the start of February 2020, those stocks would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,105.36.

Johnson-and-Johnson stock price

Use our graph to track the performance of JNJ stocks over time.

Johnson-and-Johnson stocks at a glance

Information last updated 2021-07-29.
Latest market close$165.97
52-week range$131.0873 - $173.38
50-day moving average $167.1334
200-day moving average $164.6765
Wall St. target price$187.39
PE ratio 25.8839
Dividend yield $4.09 (2.38%)
Earnings per share (TTM) $6.652

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Johnson-and-Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Johnson-and-Johnson price performance over time

Historical closes compared with the last close of $165.97

1 month (2021-07-01) 0.01%
3 months (2021-04-30) 1.99%

Is Johnson-and-Johnson under- or over-valued?

Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson-and-Johnson's P/E ratio

Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Johnson-and-Johnson stocks trade at around 26x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

Johnson-and-Johnson's PEG ratio

Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8994. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Johnson-and-Johnson's EBITDA

Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$30.6 billion.

The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson-and-Johnson financials

Revenue TTM USD$89.2 billion
Operating margin TTM 25.81%
Gross profit TTM USD$54.3 billion
Return on assets TTM 7.98%
Return on equity TTM -9999999%
Profit margin 19.92%
Book value $25.006
Market capitalisation USD$453.4 billion

TTM: trailing 12 months

How to short and sell Johnson-and-Johnson stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "JNJ.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 15.8 million Johnson-and-Johnson stocks held short by investors – that's known as Johnson-and-Johnson's "short interest". This figure is 4% up from 15.2 million last month.

There are a few different ways that this level of interest in shorting Johnson-and-Johnson stocks can be evaluated.

Johnson-and-Johnson's "short interest ratio" (SIR)

Johnson-and-Johnson's "short interest ratio" (SIR) is the quantity of Johnson-and-Johnson stocks currently shorted divided by the average quantity of Johnson-and-Johnson stocks traded daily (recently around 6.5 million). Johnson-and-Johnson's SIR currently stands at 2.41. In other words for every 100,000 Johnson-and-Johnson stocks traded daily on the market, roughly 2410 stocks are currently held short.

However Johnson-and-Johnson's short interest can also be evaluated against the total number of Johnson-and-Johnson stocks, or, against the total number of tradable Johnson-and-Johnson stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson-and-Johnson's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Johnson-and-Johnson stocks in existence, roughly 10 stocks are currently held short) or 0.006% of the tradable stocks (for every 100,000 tradable Johnson-and-Johnson stocks, roughly 6 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Johnson-and-Johnson.

Find out more about how you can short Johnson-and-Johnson stock.

Johnson-and-Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson-and-Johnson's total ESG risk score

Total ESG risk: 35.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson-and-Johnson's environmental score

Environmental score: 3.79/100

Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson-and-Johnson's social score

Social score: 25.14/100

Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson-and-Johnson's governance score

Governance score: 14.87/100

Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson-and-Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.

Environmental, social, and governance (ESG) summary

Johnson & Johnson was last rated for ESG on: 2019-01-01.

Total ESG score 35.8
Total ESG percentile 72.38
Environmental score 3.79
Environmental score percentile 7
Social score 25.14
Social score percentile 7
Governance score 14.87
Governance score percentile 7
Level of controversy 4

Johnson-and-Johnson stock dividends

38%

Dividend payout ratio: 38.33% of net profits

Recently Johnson-and-Johnson has paid out, on average, around 38.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.46% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.46% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.09 per share.

While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.

Johnson-and-Johnson's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their stocks by 23 August 2021 (the "ex-dividend date").

Have Johnson-and-Johnson stocks ever split?

Johnson-and-Johnson stocks were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Johnson-and-Johnson stocks which in turn could have impacted Johnson-and-Johnson's stock price.

Johnson-and-Johnson stock price volatility

Over the last 12 months, Johnson-and-Johnson's stocks have ranged in value from as little as $131.0873 up to $173.38. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.7111. This would suggest that Johnson-and-Johnson's stocks are less volatile than average (for this exchange).

Johnson-and-Johnson overview

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site